Disposition of the bromosulfophthalein-glutathione conjugate in the isolated perfused rat kidney by Snel, C.A.W. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/21818
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
0022-3665/95/2733-1300$03.00/0
T h e  J o u r n a l  o f  P h a r m a c o lo g y  a n d  E x p e r im e n t a l  T h e r a p e u t ic s  273> No. 3
Copyright © 1995 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A,
JPET 273-.130Q—13Q6, 1995
Disposition of the Bromosulfophthalein-Glutathione Conjugate 
in the Isolated Perfused Rat Kidney
C. A. WILCO SNEL, MIEK M. MOONS, FRANS G. M. RUSSEL and GERARD J. MULDER
Division o f Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands [C.A.W.S., G.J.M.] and 
Department o f Pharmacology, Faculty o f Medical Sciences, University o f Nijmegen, Nijmegen, The Netherfands [M.M.M,, F.G.M.R.]
Accepted for publication February 21, 1995
‘ ABSTRACT
Rena! elimination of the bromosulfophthalein-glutathione con­
jugate (BSP-GSH) after its i.v. administration in the rat in vivo is 
negligible. In our study we wanted to establish whether the high 
albumin-binding of BSP-GSH constitutes the major restrictive 
factor toward the urinary excretion of the compound. The renal 
disposition of BSP-GSH was studied in the isolated rat kidney 
during perfusions with or without albumin in the perfusate. The 
urinary clearance of BSP-GSH in the absence of albumin was 
very low (<60 jul/min) as compared to the inulin clearance 
{approximately 300 /xl/min). This indicates that albumin-binding 
is not the major reason for the low urinary clearance of BSP- 
GSH. Addition of albumin to the perfusate further decreased 
the urinary excretion by 60%. BSP-GSH is metabolized by the
kidney Into two major metabolites; the cysteinylglycine conju­
gate and the di-giutathione conjugate. Both metabolites appear 
in perfusate, which suggests that BSP-GSH undergoes tubular 
(re-)uptake. The di-glutathione conjugate is further metabolized 
to the di-cysteinylglycine conjugate. The di-glutathione conju­
gate and the di-cysteinylglycine conjugate are the major urinary 
components and the urinary elimination of BSP-GSH may de­
pend on their formation. Inhibition of 7-glutamyl transpeptidase 
activity with acivicin largely prevented the degradation to the 
cysteinylglycine and dicysteinylglycine conjugates of BSP. The 
total rate of urinary excretion, however, was only slightly low­
ered by acivicin. Apparently, cleavage of the 7-glutamyl moiety 
is not relevant for the total urinary elimination of BSP-GSH.
The liver diagnostic dye BSP is commonly "used as model 
compound for studies on hepatic uptake mechanisms and as 
substrate for GSH conjugation. In the rat, BSP is metabo­
lized in the liver to yield the BSP-GSH conjugate (Krebs and 
Brauer, 1958; Grodsky et aLs 1959; Combes and Stakelum, 
1960; Combes, 1965; Whelan et al., 1970). Degradation of 
BSP-GSH to cysteinylglycine and cysteine conjugates, as well 
as the formation of di-GSH conjugates and derived metabo­
lites, has been reported (Sano et aL, 1992), but these path­
ways are quantitatively negligible. BSP and BSP-GSH are 
both tightly bound to albumin (Baker and Bradley, 1966; 
Pfaff et al,, 1975), and their hepatic uptake is thought to 
proceed via an albumin-mediated uptake mechanism (Levi 
et al., 1969; Scharschmidt et aL, 1975; Weisiger et al.y 1981; 
Theilrnann et aL, 1984).
In the rat in vivo, BSP is mostly eliminated by the liver 
(Klaassen, 1975; Yam et aL, 1976; Snel et ah, 1995). The 
same observation has been made for the BSP-GSH conjugate: 
when BSP-GSH is administered i.v., the dose is virtually 
completely recovered in bile, mostly as unchanged compound 
(Yam et al.s 1976; Snel et al., 1995). Urinary elimination of
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BSP-GSH appears to be a very minor excretory pathway. In 
this respect, the disposition of BSP-GSH differs from that of 
most other GSH conjugates, which are readily excreted in 
urine after renal biotransformation to mercaptures (Inoue et 
a i , 1982). Unlike many other GSH conjugates, BSP-GSH is 
tightly bound to albumin: 99% is bound under physiological 
conditions (Baker and Bradley, 1966). When the dissociation 
rate of BSP-GSH from albumin is low in comparison to the 
transit rate of albumin-bound BSP-GSH through the glomer­
uli, albumin-binding may be the reason why BSP-GSH is 
poorly filtered by the glomeruli and why the urinary excre­
tion is very small.
In our study, we wanted to establish whether albumin- 
binding is indeed the reason for the poor renal elimination of 
BSP-GSH. The disposition of BSP-GSH was studied in the 
isolated perfused rat kidney during perfusions with or with­
out albumin in the perfusate.
Methods
Chemicals. BSP was purchased from Janssen Chimica, Geel, 
Belgium. Reduced GSH was from E. Merck, Darmstadt, Germany.
Acivicin [L-(aS,5S)-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic
ABBREVIATIONS: BSP, bromosulfophthalein; GSH, glutathione; BSP-GSH, glutathione conjugate of BSP; BSP-cys-gly, cysteinylglycine conju­
gate of BSP; BSP-(GSH)2, diglutathione conjugate of BSP; BSP-(cys-giy)2, dicysteinylglycine conjugate of BSP; HPLC, high-performance liquid 
chromatography.
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acid; AT-125] was purchased from Sigma Chemical Co., St. Louis, 
MO. BSP-GSH was prepared according to the method of Whelan et 
al, (1970); the reaction product contained BSP-(GSH)2 as a chemical 
impurity (approximately 10%). The cysteinylglycine conjugates of 
BSP-GSH and BSP-(GSH)a were prepared as described previously 
(Snel et al., 1993). Iieparin, insulin and aldosterone were from 
Organon B.V., Oss, The Netherlands. Lysine-vasopressine was from 
Sandoz, Basel, Switzerland. Angiotensin was from Beckmann, Palo 
Alto, CA. Synthamin 14 w as from Travenol, Thetford, U.K.
Isolated perfused rat kidney. Male Wistar rats (University of 
Nijmegen; 225-275 g body weight) were used as kidney donors. 
Surgery was conducted under sodium pentobarbital anesthesia (45 
mg/100 g) as described in detail by Cox et al, (19B9). Briefly, furo- 
semide (1 mg/100 g) was administered i.p. and heparin (125 IU/100 
g) was administered i.v. via a cannula in the femoral vein. The 
abdomen was opened and the right kidney was freed from adhering 
tissue. After cannulation of the ureter, the right renal artery was 
cannulated via the mesenteric artery, The kidney was excised and 
transferred into a waterbath with a constant temperature» of 37.5C5C. 
Renal perfusion was maintained by a peristaltic roller pump and 
renal pressure was measured with a pressure transducer, During the 
first 5 to 10 min of the perfusion, the venous effluent was discarded. 
Hereafter, the perfusion fluid was recirculated and the kidney was 
allowed to stabilize for 30 min. During this period, no urine or 
perfusate samples were taken. Subsequently, urine was collected at 
10-min intervals during a control period of 20 min. In this control 
period, the volume of the recirculating perfusion fluid was 500 ml.
The perfusion fluid had the following composition: 114.0 mM 
NaCl, 5.2 mM KC1,1.8 mM CaCl2, 1.0 mM MgCl2> 22.5 mM NaHC03) 
0.84 mM NaaHP04, 0.28 mM KH2P 04, 5.0 mM glucose, 4.0 mM urea, 
0.330 mM glutathione, 0.083 mM D-inositol, 0.50 mM L-cysteine, 2.30 
mM glycine, 2.00 mM sodium pyruvate, 1.22 mM sodium acetate, 
0.208 mM sodium propionate, 1.00 mM inosine, 5.00 mM L-alanine, 
0.106 mM L-glutamine, 2.00 mM L-glutamic acid, 1,15 mM a-ketogl- 
utaric acid, 0.01 mM L-ascorbic acid, 1.0 mM sodium lactate, 0.125 
g/liter inulin, 1.0 mg/liter choline chloride, 4 IU/liter insulin, 2.0 
jLig/liter aldosterone, 0.01 IU/liter lysine-vasopressin, 15.0 ng/liter 
angiotensin II and 1.0% synthamin 14 (a mixture of 14 amino acids). 
In addition, the perfusate contained either 2.5% (w/v) pluronic F108 
(albumin-free perfusate) or 2.2% (w/v) pluronic F108 plus 2.0% (w/v) 
bovine serum albumin (albumin-containing perfusate), depending on 
the perfusate composition during the experimental period.
At the end of the control period, a new perfusate reservoir was 
connected with a total perfusate volume of 150 ml. Two experimental 
groups were distinguished on the basis of the perfusate composition: 
perfusate in one group contained 2.5% pluronic F10S (albumin-free 
perfusate); in the other group, it contained 2.2% pluronic F108 plus 
2.0% bovine serum albumin (albumin-containing perfusate). In both 
groups, the recirculating perfusate contained 37 fiM BSP-GSH at the 
beginning of the experimental period.
In a third group of kidney perfusions, the role of cleavage of the 
y-glutamyl moiety in renal handling of BSP-GSH was investigated. 
Perfusate in the experimental period contained 2.5% pluronic F108, 
37 fiM BSP-GSH and 1.0 mM acivicin. Acivicin is a glutamine an­
tagonist which inhibits y-glutamyl transpeptidase (Anderson et al., 
1980; Tanaka-Kagawa et aL, 1993); 1 mM acivicin has been shown to 
inhibit the renal and intestinal activities in vitro by more than 95% 
(Reed et a l , 1980; Dahm and Jones, 1994).
The perfusion fluids were filtered before (0.22 fxm pores) and 
during (5,0 /xm pores) the experiment. The solution was oxygenated 
with a flow-through oxygenator, using 95% oxygen: 5% carbon diox­
ide. Perfusion flow was adjusted to renal perfusion pressure (90 mm 
Hg) and amounted to 11 to 17 ml/min with albumin-free perfusate 
and 21 to 22 ml/min with albumin-containing perfusate. Renal per­
fusion pressure was measured with a pressure transducer near the 
entry of the catheter; typically, the perfusion pressure did not change 
in the course of the perfusion. The urine flow rate and urinary pH 
were measured during the experiment with aid of a bubble flowmeter
and a flow-through pH meter, respectively. The GFR was calculated 
on the basis of inulin clearance as follows: GFR = ([inulin]urino/ 
[inulin ]perfusate) x urine flow rate. Inulin concentrations in urine and 
perfusate were determined by the method of Heyrovsky (1956).
The experimental period lasted for 90 min, during which urine 
samples were collected at 10-min intervals. Perfusate samples (250 
jil) were taken from the reservoir at the TTOid of the urine collection 
interval. An additional perfusate sample was taken at the end of the 
perfusion. Perfusate and urine samples were stored at —20°C until 
analysis.
Analytical methods. BSP-GSH in perfusate was quantitated by 
a previously reported HPLC method (Snel et a l,  1992), but with 
some minor modifications. The separation was achieved on a stain­
less steel column (150 X 3 mm i.d.), packed with 5-/xm particles of 
Spherisorb ODS2 reversed phase material. The system comprised a 
S1000 solvent delivery system, a S2110 low pressure mixer, a S2000 
HPLC controller (Sykam, Gauting, Germany) and a Promis II au­
tosampler (Separations Analytical Instruments, Emmen, The Neth­
erlands). Elution solvent A was a 10 mM sodium phosphate buffer, 
pH 6.0; solvent B was acetonitrile. The following elution profile was 
used at a constant flow rate of 0,55 ml/min; isocratic conditions (0% 
B) were maintained for 2.5 min. followed by a linear gradient to 30% 
B in 15 min. Hereafter the system was reverted to the initial condi­
tions in 2.5 min and allowed an equilibration interval of ü min for the 
next injection. UV detection was achieved with a spectrophotometer 
(Waters Associates Inc., Milford, MA) at a wavelength of 254 nm.
Perfusate samples without albumin were diluted 10-fold with 10 
mM sodium phosphate buffer, pH 6.0. The diluted sampler were 
directly injected onto the HPLC system. The albumin-containing 
perfusate samples were first mixed with a saturated urea solution 
(100 /d sample + 100 ju,l urea solution). Hereafter, proteins were 
precipitated by addition of 800 fxl acetonitrile and subsequent cen­
trifugation; 900 jul of the supernatant were transferred to another 
tube and dried under a stream of nitrogen gas. The residue was 
reconstituted in 900 p,l 10 mM sodium phosphate buffer, pH 6.0. The 
obtained solution was injected onto the HPLC. A series of BSP-GSH 
solutions (10-100 juM) in blank perfusate (with or without albumin) 
was processed as described above for the experimental samples and 
furnished the calibration curve.
Urine and perfusate samples were also analyzed spectrophoto- 
metrically at 578 nm without prior separation of the compounds that 
absorb at this wavelength. Samples were diluted 10-fold with a 0.1 N 
sodium hydroxide solution and the absorbance was read at 578 nm. 
A series of BSP-GSH solutions (10-100 / j M )  in blank urine or blank 
perfusate was diluted as described for the experimental samples and 
furnished the calibration curve, For quantitative purposes, it was 
assumed that BSP-GSH derived metabolites possess the same molar 
extinction coefficient as BSP-GSH.
Identification of BSP-GSH-derived m etabolites. For the 
identification of BSP-GSH-derived metabolites in perfusate and 
urine, a higher degree of selectivity of detection was needed. There­
fore, the HPLC separation methodology was combined with post­
column alkalinization and spectrophotometric detection of the pur­
ple chromophores at 578 nm, a principle previously described by 
Van’t Klooster et al, (1988). A 0.05 N sodium hydroxide solution in 
water/acetonitrile = 80/20 (v/v) was delivered by a HPLC pump 
(Water Associates Inc., Milford, MA) at a flow rate of 0.2 ml/min, and 
added to the eluent from the column via a T connection. A mixing coil 
was placed between the T connection and the d-îtector. Highly selec­
tive detection of BSP-GSH and its metabolites vas achieved with a 
variable wavelength Spectroflow 757 spectrophotometer (Kratos An­
alytical, Ramsey, NJ) at a wavelength of 578 nr\.
This method of detection was also used to check the stability of 
BSP-GSH in perfusate and in urine samples: blame albumin-contain­
ing and albumin-free perfusate (perfused through the kidney for 20 
min), and blank urine were spiked with BSP-GSH (37 /xM) and 
incubated at 37°C. Samples were taken every hour for a total period 
of 6 h, and immediately processed as described above for HPLC
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analysis. BSP-GSH and BSP-(GSH)2 (which was present as a minor 
chemical impurity) were found to be stable under these conditions.
Protein b inding o f BSP-GSH. Unbound BSP-GSH in albumin- 
containing perfusate was isolated by ultrafiltration. Albumin-con­
taining perfusate was spiked with BSP-GSH (37 jxM) and incubated 
for 1 h at 37°C. The perfusate was then centrifuged at 37°C for 30 
min at 2000 X g  through YMT membranes (Amicon micropartition 
system; Amicon Inc., Beverly, MA), The BSP-GSH concentration in 
total perfusate and ultrafiltrate samples was determined spectro- 
photometrically as described above. The unbound fraction was cal­
culated as: [BSP-GSH] in ultrafiltrate/[BSP-GSH] in total perfusate.
Data analysis. The statistical significance of differences between 
the experimental groups was evaluated, using an analysis of vari­
ance test, A comparison for each individual time point was made 
between the experiments with albumin-free perfusate and albumin- 
' containing perfusate, and between the experiments with albumin- 
free perfusate and albumin-free/acivicin-containing perfusate, A 
comparison between the experiments with albumin-containing per­
fusate and albumin-free/acivicin-containing perfusate was omitted. 
A P- < .05 was considered significant.
The renal clearance of BSP-GSH (CL) was calculated in two ways:
Clr «
[BSP — GSH metabolites]urine 
[BSP - GSHJperfuaate
X urine flow rate*
CL
[BSP -  GSH + metabolites]urine
[BSP -  GSH + metabolites]perfU8ate
X urine fluw rate.
Results
Evaluation o f renal function during the kidney per­
fusions. Kenal function was monitored during the control 
and experimental period by determination of GFR, urine flow 
rate and urinary pH (fig. 1). Throughout the control and 
experimental period, the urinary pH and GFR were not sig­
nificantly different between the compared groups. During the 
last 30 min of the experimental period (60-90 min), the urine 
flow rate was significantly higher in perfusion with albumin- 
free/acivicin-containing perfusate than in perfusions with 
albumin-free perfusate without acivicin, The GFR and the 
urine flow rate did not change in the course of the perfusion. 
The urinary pH, however, showed a tendency to increase in 
all perfusions.
Elim ination o f BSP-GSH from perfusate; effect of 
albumin. Kidney perfusions were conducted with or without 
albumin in the perfusate. The BSP-GSH concentration in the 
recirculating perfusion medium decreased rapidly in the ab­
sence of albumin (fig. 2a). This was due to its conversion to 
metabolites: the total concentration of BSP-GSH plus its 
metabolites in perfusate decreased only very little during the 
perfusion (fig. 2b). Albumin decreased the rate of disappear­
ance of BSP-GSH from the recirculating perfusate (fig. 2a); 
from 30 to 90 min, differences between the two experimental 
groups in the BSP-GSH concentration in perfusate were sta­
tistically significant. Albumin, however, did not affect the 
rate of disappearance of BSP-GSH plus its metabolites (fig. 
2b); the concentration-time profiles were virtually identical 
for the two experimental groups.
To identify the BSP-GSH derived metabolites, the recircu­
lating perfusate at the end of the perfusion was analyzed by 
HPLC with post-column alkalinization and spectrophotomet- 
ric detection at 578 nm. This procedure revealed the presence 
of two BSP-GSH-derived metabolites (fig. 3); with the aid of 
reference compounds, they were identified as the disubsti­
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Fig. 1. Glomerular filtration rate (GFR), urinary pH and urine flow rate as 
parameters for kidney function during the control period ( - 2 0 - 0  min) 
and experimental period (0-90 min) of the kidney perfusion. During the 
experimental period, perfusate initially contained 37 fiM BSP-GSH in all 
three experimental groups. Furthermore, perfusate contained 2.5% 
pluronic F108 (O), 2.2% pluronic F108 + 2.0% bovine serum albumin 
( • )  or 2.5% pluronic F108 + 1.0 mM acivicin (A). Data points represent 
means ±  S.D.; n =  4 for the first two groups, n =* 3 for the third group.
tuted BSP-(GSH)2 and the cysteinylglycine conjugate of BSP 
(BSP-cys-gly). The relative contribution of the components 
was different for the two experimental groups: the contribu­
tion of BSP-cys-gly appeared to be higher in albumin-free 
than in albumin-containing perfusate.
Excretion of BSP-GSH and its metabolites in urine: effect 
of albumin
Total urinary excretion rates (without differentiation be­
tween BSP-GSH and its metabolites) were estimated spec- 
tropho tome trie ally at 578 nm after alkalinization of the urine 
samples. Throughout the experiment, excretion rates were 
significantly higher in perfusions with albumin-free perfu­
sate than in perfusions with albumin-containing perfusate
1995
Time (m in)
3
Time (m in)
Fig. 2. BSP-GSH concentrations (a) and total concentrations of BSP- 
GSH +  metabolites (b) in recirculating perfusate during the experimen­
tal period of the kidney perfusion. The experimental groups and the 
corresponding symbols are the same as those in figure 1.
(fig. 4). Excretion rates kept increasing slowly during the 
experiment; steady-state conditions were not reached within 
the duration of the perfusion.
Urine samples, collected between 80 to 90 min of the ex­
perimental period, were subjected to HPLC analysis with 
post-column alkalinization and spectrophotometric detection 
at 578 nm in order to characterize the urinary metabolite 
pattern. The compounds present were identified as un­
changed BSP-GSH, BSP-(GSH)2 and the two corresponding 
cysteinylglycine conjugates, BSP-cys-gly and BSP-(cys-gly)2, 
respectively (fig. 3). The (twin) peak that was identified as 
BSP-(cys-gly)2 may actually represent a mixture of the di- 
cysteinylglycine conjugate and the mono-cysteinylglycine- 
mono-glutathione conjugate of BSP. The relative contribu­
tion of the urinary components was calculated, assuming 
identical molar extinction coefficients. Approximately 70% of 
the total amount in urine consisted of the diconjugates, BSP- 
(GSH)2 and BSP-(cys-gly)2> both in the absence and in the 
presence of albumin in the perfusate (table 1).
Effect of y- glut amyl transpeptidase inhibition by 
acivicin The effect of acivicin, an inhibitor of the y-glutamyl 
transpeptidase activity, was studied to assess a possible role 
of cleavage of the y-glutamyl group in the renal clearance of 
BSP-GSH. Acivicin was added to a concentration of 1 mM to 
the recirculating (albumin-free) perfusate.
Acivicin decreased the rate of disappearance of BSP-GSH 
from perfusate (fig. 2a); differences between the two groups 
were significant from 20 to 90 min of the experimental pe­
riod, The total concentration of BSP-GSH and its metabolites 
in perfusate decreased very little during the perfusion (fig. 
2b); the concentration-time profile did not differ between the 
two groups. Application of the HPLC post-column alkaliniza­
tion procedure demonstrated that BSP-cys-gly was absent 
from the perfusate at the end of the perfusion (fig. 3); perfu­
sate only contained BSP-GSH and BSP-(GSH)2,
Total urinary excretion rates (without differentiation be­
tween the urinary metabolites) were lower, but not signifi­
cantly different from the excretion rates in perfusions with­
out acivicin (fig. 4). The urinary metabolite pattern, however, 
differed considerably between the two experimental groups 
(table 1): in perfusions with acivicin, BSP-GSH and BSP- 
(GSH)2 accounted for 75% of the total amount in urine, 
whereas in absence of acivicin, their contribution amounted 
to only 15% and the corresponding cysteinylglycine conju­
gates were predominant.
Protein binding o f BSP-GSH in  perfusate. The un­
bound fraction of synthetic BSP-GSH in albumin-containing 
perfusate was found to be 14%,
Discussion
The urinary elimination of BSP-GSH was clearly restricted 
by binding to albumin. The urinary BSP-GSH clearance (fig. 
5a) in the presence of albumin was approximately 20% of that 
in the absence of albumin in the perfusate; this seems to 
agree reasonably well with the 14% unbound fraction. How­
ever, albumin-binding can not account for the low urinary 
clearance: in the absence of albumin, the total urinary clear­
ance of BSP-GSH was still very low (maximally 60 /xl/min; 
see fig. 5a), compared to that of inulin (260-310 /il/min). 
Unless for some unknown reason BSP-GSH is not filtered in 
the glomeruli, this suggests that tubular reuptake of BSP- 
GSH plays an important role. This seems to be supported by 
the fact that the urinary clearance of BSP-GSH (mainly in 
the form of metabolites) slowly increased in the course of the 
perfusion, whereas that of inulin was more or less constant: 
a possible explanation for the increase of the urinary clear­
ance is that the metabolites that accumulated in the course of 
the perfusion were more efficiently excreted in urine than 
unchanged BSP-GSH.
BSP-cys-gly and BSP-(GSH)2 appeared to be the major 
metabolites of BSP-GSH formed in the kidney. BSP-cys-gly is 
probably generated in the lumen of the proximal tubule, 
because its formation is catalyzed by y-glutamyl transpepti­
dase, an enzyme that is abundantly present in the brush- 
border membrane at the apical side of proximal tubular cells 
(Rutenberg et al., 1969; Glossmann and Neville, 1972). How­
ever, BSP-cys-gly is not only recovered in urine, but also in 
perfusate. Therefore, it seems that BSP-cys-gly undergoes 
tubular reuptake from the lumen or that BSP-cys-gly is 
formed during reuptake of BSP-GSH. Alternatively, BSP- 
cys-gly in the perfusate may be formed by y-glutamyl 
transpeptidase at the basolateral side of the cells.
The formation of the BSP-(GSH)2 conjugate must take 
place intracellularly, possibly in the proximal tubular cells. 
This requires (tubular re-)uptake of BSP-GSH. BSP-(GSH)2 
appears in the perfusate and probably undergoes glomerular
Renal Disposition of BSP-GSH 1303
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matograms of HPLC analysis 
with post-column aikalinization 
and spectrophotometric detec­
tion at 578 nm of perfusate 
samples (A, B and C) and urine 
samples (D, E and F) at the end 
of the perfusion. Perfusate con­
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Fig. 4. Total urinary excretion rates (without differentiation between 
BSP-GSH and its metabolites) during the experimental period of the 
kidney perfusion. The experimental groups and the corresponding sym­
bols are the same as those in figure 1.
filtration and degradation to BSP-(cys-gly)2 in the lumen of 
the proximal tubule. Although tubular reuptake of BSP-(cys- 
gly)2 is unlikely, because this metabolite was not detected in 
the perfusate at the end of the perfusion, uptake by the
TABLE 1
Urinary metabolite pattern: relative contribution of BSP-GSH and 
its metabolites to the total amount excreted in urine between 80 
to 90 min of the experimental period (%) (averages of duplicate 
values are shown)
n Urinary Metabolite
Perfusate Composition
2.5%
pluronic
2.2% pluronic + 2.5% pluronic + 
2.0% albumin 1 mM acivicin
1. BSP-(GSH)2 9 19 37
2. BSP-(cys-gly)2 60 53 19
3. BSP-GSH 6 9 37
4. BSP-cys-gly 25 18 6
tubular cells followed by local sequestration or metabolism 
can not be ruled out with certainty.
BSP-(GSH)2 and BSP-(cys-gly)2 constitute the major uri­
nary components. The urinary clearance of BSP-GSH may 
largely depend on their formation.
To study whether y-glutamyl transpeptidase catalyzed 
degradation interferes with the renal clearance of BSP-GSH, 
kidney perfusions were conducted with the y-glutamyl 
transpeptidase inhibitor acivicin in albumin-free perfusate. 
Acivicin effectively prevented the conversion of BSP-GSH
1995 Renat Disposition of BSP-GSH 1305
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Fig. 5. Urinary clearance of BSP-GSH during the experimental period of 
the kidney perfusion. Urinary clearance (Clr) was calculated in two 
ways:
C!r =
[BSP ~  GSH H- metabolites] unna
cir -
[BSP GSH]pQrfUSQte 
[BSP ~ GSH H* metabolites]
x  urine flow rate (a)
urins
[BSP -  GSH + metabolites]perfusate
x  urine flow rate (b)
The experimental groups and the corresponding symbols are the same 
as those in figure 1.
and BSP-(GSH)2 to the corresponding cysteinylglycine con­
jugates, as indicated by the absence of BSP-cys-gly from the 
recirculating perfusate (at the end of the perfusion), as well 
as by the much reduced contribution of BSP-cys-gly and 
BSP-(cys-gly)2 to the urinary metabolite pattern. The rate of 
disappearance of BSP-GSH from perfusate was much de­
creased by addition of acivicin, which suggests that the rapid 
decline of the BSP-GSH concentration in the absence of acivi­
cin was mostly due to conversion of BSP-GSH to BSP-cys-gly. 
The total rate of urinary excretion was somewhat lowered by 
addition of acivicin, but the difference was not statistically 
significant. Apparently, inhibition of y-glutamyl transpepti­
dase has little effect on the urinary elimination of BSP-GSH.
A possible model that explains all the results involves 
glomerular filtration of BSP-GSH, followed by degradation of 
BSP-GSH to BSP-cys-gly in the tubular lumen. Both BSP- 
GSH and BSP-cys-gly then undergo active (re-)uptake by 
proximal tubular cells. Intracellularly, substitution of a sec­
ond GSH moiety takes place to give the BSP-(GSH)2 conju­
gate. BSP-GSH, BSP-cys-gly and BSP-(GSH)2 are secreted
into the perfusate and undergo glomerular filtration during 
second passage through the kidney; the di-glutathione con­
jugate may also be excreted directly into the lumen. Inside 
the tubular lumen, BSP-(GSH)2 is degraded to BSP-(cys- 
gly)2. Limited or no reuptake of BSP-(GSH)2 and BSP-(cys- 
gly)2 by proximal tubular cells results in their excretion in 
urine. As BSP-(GSH)2 accumulates in the recirculating per­
fusate in the course of the perfusion, total urinary excretion 
rates increase with time. Essentially, this model is based on 
a high rate of tubular reuptake of BSP-GSH and little or no 
reuptake of BSP-(GSH)2 and BSP-(cys-gly)2. In view of this, 
the clearance values of Fig. 5a and 5b have to be interpreted 
with caution.
In this report, we have studied the disposition of BSP-GSH 
in the isolated perfused rat kidney to elucidate the poor 
urinary elimination of BSP-GSH in the rat in vivo. As ex­
pected, protein binding does indeed play a restrictive role 
toward the urinary excretion of BSP-GSH, but a high rate of 
tubular reabsorption appears to be another important factor 
explaining the low urinary clearance.
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